Revelation Biosciences (REVB) director gets 41,981 RSUs at $0.90

Rhea-AI Filing Summary

Revelation Biosciences director Jess Roper reported receiving an equity award of 41,981 shares of common stock on January 8, 2026 at a price of $0.90 per share. After this grant, Roper directly beneficially owns 57,667 shares of the company’s common stock.

The award is described as a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing also reflects an existing direct holding of 15,686 common shares, separate from the new restricted stock unit award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROPER JESS

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								15,686	D
Common Stock(1)	01/08/2026		A		41,981	A	$0.9	57,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

	/s/ J.P. Galda, as attorney-in-fact for Jess Roper	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Revelation Biosciences (REVB) report for Jess Roper?

Director Jess Roper reported an award of 41,981 shares of Revelation Biosciences common stock on January 8, 2026, recorded at $0.90 per share.

How many Revelation Biosciences (REVB) shares does Jess Roper own after this transaction?

Following the reported grant, Jess Roper directly beneficially owns 57,667 shares of Revelation Biosciences common stock.

What type of equity award did Jess Roper receive from Revelation Biosciences (REVB)?

The award is a Restricted Stock Unit grant under the company’s 2021 Equity Incentive Plan, linked to Revelation Biosciences common stock.

What is the vesting schedule for Jess Roper’s restricted stock units at Revelation Biosciences (REVB)?

The restricted stock units granted to Jess Roper vest quarterly over one year from the January 8, 2026 grant date.

What was the reported price per share for Jess Roper’s Revelation Biosciences (REVB) equity award?

The 41,981-share equity award was reported at a price of $0.90 per share for Revelation Biosciences common stock.

What is Jess Roper’s role at Revelation Biosciences (REVB)?

Jess Roper is identified as a director of Revelation Biosciences, Inc. and is not listed as an officer or 10% owner in the report.